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Abstract: 
Background: Digoxin was found to inhibit prostate cancer (PCa) growth via the inhibition of HIF-1α synthesis in a mouse model. We 
hypothesized that a therapeutic dose of digoxin could inhibit human PCa growth and disease progression. 
Methods: An open label, single arm pilot study was performed. Patients (pts) with non-metastatic, biochemically relapsed PCa with prostate 
specific antigen doubling time (PSADT) of 3 -24 months and no hormonal therapy within the past 6 months were enrolled. All pts had 
testosterone > 50 ng/dL at baseline. Digoxin was taken daily with dose titration to achieve a target therapeutic level (0.8 – 2 ng/ml); patients 
had routine follow-up including cardiac monitoring with 12-lead electrocardiograms (ECGs) and digoxin levels. The primary endpoint was 
the proportion of pts at 6 months post-treatment with a PSADT > 200% from the baseline. HIF-1α downstream molecule vascular endothelial 
growth factor (VEGF) was measured in plasma. 
Results: Sixteen pts were enrolled and 14 pts finished the planned 6 months of treatment. Twenty percent (3/15) of the pts had PSA 
decrease >25% from baseline with a medium duration of 14 months. At 6 months, 5 of 13 (38%) pts had PSADT > 200% of the baseline 
PSADT and were continued on study for an additional 24 weeks of treatment. Two patients had durable PSA response for more than 1 year. 
Digoxin was well tolerated with possible relation of one grade 3 back pain. No patients had evidence of digoxin toxicity. The digoxin dose 
was lowered in 2 patients for significant ECGs changes (sinus bradycardia and QT prolongation), and there were probable digoxin-related 
ECG changes in 3 patients. Plasma VEGF was detected in 4 (25%) patients.   
Conclusions: Digoxin was well tolerated and showed a prolongation of PSDAT in 38% of the patients. However, there was no significant 
difference comparing that of similar patients on placebo from historical data. Digoxin at the dose used in this study may have limited benefit 
for patients with biochemically relapsed prostate cancer. 
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Background  
Biochemically-relapsed, non-metastatic, hormone-naïve prostate cancer (PCa) represents a unique 
disease state [1, 2]. As many as 70,000 men per year in the United States fall into this category where a 
rising prostate specific antigen (PSA) is the only manifestation of illness [2, 3]. In men with PSA 
progression after local therapy, management options include salvage radiation, surveillance, dietary 
intervention, clinical trial participation or initiation of androgen deprivation therapy (ADT) [4, 5]. 
However, no definite survival benefit has been demonstrated with the early institution of ADT in this 
population. Given the adverse effects of ADT, many men choose to avoid or delay medical castration for 
a rising PSA alone. Developing alternative options for patients with “PSA-only” PCa is therefore 
highly desirable. 
Clinical trials have been conducted using a variety of non-hormonal therapies to treat PSA recurrent 
PCa. These reagents include granulocyte-macrophage colony-stimulating factor[6], High dose vitamin D 
using weekly oral calcitriol [7], Cox-2 inhibitor Celecoxib.[8], peroxisome proliferator-activated receptor 
gamma agonist Rosiglitazone[9], tyrosine kinase inhibitor imatinib[10], copper/zinc-superoxide 
dismutase inhibitor ATN-224[11], matrix metalloproteinase inhibitor marimastat [12], 
antiangiogenic/immunomodulatory drug lenalidomide[13], pomegranate extract [14], and DNA 
methylation inhibitor disulfiram[15] etc. With different mechanisms, these agents showed some 
biological activities but still no drugs are available to treat PCa in this state.   
Recently, two independent drug library screenings for inhibitors of PCa revealed digoxin as a potent 
inhibitor of PCa cell growth [16]. Screening for agents inhibiting hypoxia induced factor -1α (HIF-1α) 
transcriptional activity identified twenty drugs as potential HIF-1α inhibitors [16]. Eleven of these drugs 
were cardiac glycosides, including digoxin, ouabain, and proscillaridin A, which inhibited HIF-1α protein 
synthesis and expression of HIF-1α target genes in cancer cells. In vitro 50 nM ouabain or proscillaridin 
A inhibited HIF-1α expression at both 20% and 1% O2 conditions in the human PCa cell line. This study 
also demonstrated that inhibition of HIF-1α expression was the critical mechanism by which digoxin and 
other cardiac glycosides inhibited the PCa growth in tumor xenografts model.  
In the longitudinal Physicians' Health Study (PHS) of 47,759 health professionals, a significantly 
decreased relative risk for PCa was observed among individuals taking digoxin for cardiac indications 
after adjustment for age (P<0.001), multiple variables (diabetes mellitus, physical activity, body mass 
index, height, family history, race, pack-years smoked, and dietary factors; P<0.004), or multiple 
variables plus other medications (P<0.008) [17]. A prospective clinical study using digoxin for the 
treatment of PCa is thus performed.  
Designing a clinical trial for PSA-only disease is a challenge. Though change in PSA kinetics is 
commonly used to determine the treatment response, there is no uniform consensus for a study endpoint. 
Fifty percent of PSA reduction [6, 7] or PSA doubling time (PSADT) prolongation over baseline [6-9, 14, 
18] is often used in clinical trials. In placebo controlled studies, 20 - 31% of
 
placebo-treated participants 
had favorable PSA outcomes, defined
 
as post-treatment PSADT of more than 200% of baseline PSADT 
over 6 months[8]. To compare the historical data, we defined the prolongation of PSADT of equal to or 
more than 200% of baseline as positive PSA outcome. In this pilot study, we hypothesized that a six 
month trial of a therapeutic dose of digoxin could inhibit human PCa growth and disease progression and 
achieve a positive PSA outcome.  
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Patients and methods  
Eligibility 
Patients with histologically confirmed adenocarcinoma of prostate with evidence of biochemical relapse 
after local therapy were eligible. Patients had no detectable disease as assessed by physical examination 
and radiographic measures (bone scan and CT of the abdomen/pelvis) within 8 weeks of study entry. 
Confirmed biochemical progression was defined as three rises in PSA levels, with each PSA determined 
at least 4 weeks apart, and each PSA value increase >0.2 ng/ml with PSA doubling time (PSADT) of 3 – 
24 months. PSADT was calculated using the natural log of 2 (0.693) divided by the slope of the 
relationship of log PSA against time (in months). The last PSA level prior to enrollment had to be ≥2 
ng/mL for patients with primary radiation therapy or PSA >1 ng/ml if radical prostatectomy was 
performed. 
Patients had to be ≥18 years old, with life expectancy >6 months and Eastern Cooperative Oncology 
Group (ECOG) performance status ≤2, and with adequate hepatic, renal (creatinine < 1.5 mg/dL) and 
marrow function, serum testosterone > 50 ng/dL, no uncontrolled inter-current illness, no cardiac 
conduction disorders such as history of sinus node disease and AV Block, accessory AV Pathway 
(Wolff-Parkinson-White Syndrome), no recent history of myocardial infarction, no active other 
malignancy, no history of malabsorption syndromes.  
Prior chemotherapy was allowed as long as the requirements for adequate organ and marrow function 
were met. Patients who had radiotherapy within 3 months or other investigational agents within 28 days 
prior to the first dose of digoxin were excluded. Patients, who had hormone therapy within 6 months, 
were receiving steroids for active concurrent illness, any estrogen-like agents, or any hormonally active 
over-the-counter compounds or 5-α reductase inhibitors, were excluded.  
The institutional review board approved the study. All participants gave written informed consent.  
Study drug and design 
The study drug Digoxin is commercially available and dispensed to study participants by the Jefferson 
Investigational Drug Service (IDS) pharmacy. All patients were started at 250 mcg daily first week and 
digoxin level was checked. While waiting for the result, digoxin was given 125 mcg daily the second 
week and serum level was obtained again. The doses of week 3 and after were titrated to the serum 
digoxin level of 0.8 – 2 ng/ml for total of 6 cycles (4 weeks/cycle). The maximal dose of digoxin was 500 
mcg orally daily. ECG and digoxin were performed every 2 weeks for first cycle and then every 2 cycles 
and whenever the digoxin dose was adjusted. Digoxin dose adjustments downward were made if thought 
to be necessary by cardiology. PSA was measured every 2 cycles during the study. 
Patients were allowed to continue another 6 cycles if the primary endpoint of PSADT >200% baseline 
was met. Adverse events (AEs) were graded according to the Common Terminology Criteria for Adverse 
Events, version 3.0 (CTCAEv3).  
Baseline and follow-up evaluation 
Baseline evaluation included history and physical examination, ECG, complete blood count, 
comprehensive metabolic profile, serum testosterone, and serum PSA. Bone scan, abdominal and pelvic 
CT scans were obtained within 8 weeks prior to study entry and then every 6 cycles. At least 3 PSA 
levels, drawn ≥28 days apart, were required in order to calculate the pre-treatment PSADT. PSA levels 
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were obtained at the beginning of every 2 cycles and all values were used for kinetic calculation. PSA 
slope was calculated as the linear regression line of the natural log of PSA against time. At the end of 6 
cycles of treatment, patients were taken off the study if the primary endpoint was not met or evidence of 
radiographic metastatic disease. 
Correlative studies 
Plasma was collected before and after 2, 4, and 6 cycles of treatment and stored at -80
o
 for evaluation at 
study completion Plasma VEGF was measured at Yale School of Medicine by suspension array system 
using multiplexing technology.   
Statistical analysis  
The primary efficacy endpoint of this pilot phase II study is the proportion of patients with post treatment 
PSADT ≥ 200% of baseline without evidence of metastatic disease at 6 months after treatment with 
digoxin. The study was designed to show that treatment with digoxin could result in significantly higher 
than historical rate up to 30% of positive PSADT outcome. Exact binomial 95% confidence interval was 
computed for actually observed post-treatment rate of positive PSADT outcome.  
All patients who received one dose of digoxin were included for safety analysis and considered 
evaluable for toxicity and safety. 
Table 1 Patient characteristics at study entry (n=16) 
Age (yr) Average  66.5 
Range 48-83 
Race White (14/16) 87.5% 
Non-White (2/16) 12.5% 
Gleason score sum 
(%) 
≥ 7 (13/16) [GS 8 4 pts] 81.3% 
< 7(3/16) 18.7% 
Baseline PSA 
(ng/ml) 
Mean+/- SD 3.9+/-2.1 
Median 3.5 
Range 1.5-8.2 
PSADT prior to  
treatment (M) 
Average 8.3 
Range 2.7-20.4 
 
 
Prior treatment 
Prostatectomy only (1/16) 6.25% 
Radiotherapy only (3/16) 18.75% 
Prostatectomy and salvage Radiotherapy (9/16)  56.25% 
Radiotherapy and hormonal therapy (1/16) 6.25% 
Prostatectomy and salvage Radiotherapy and hormonal therapy (2/16) 12.5% 
 Intermittent hormonal therapy (4/16)  
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Results 
Patient characteristics 
Total 16 patients were enrolled in the study. Two patients did not finish 6 cycles treatment. One patient 
concerned the rising PSA and withdrew from the study. Another patient developed severe back pain after 3 
cycles’ treatment. It was not cancer related and the etiology was not clear. We thought this was possibly 
related to study drug and took him off the study. On retrospective review, one patient did not meet 
eligibility criteria (baseline PSADT <3 months). Although he is included in the data analysis for toxicity, 
he is not included in the statistical analysis of PSA kinetics (efficacy evaluation). Table 1 lists the patient 
characteristics upon study entry.  
PSA kinetics 
PSA Doubling Time 
The PSA kinetics was calculated within the treatment time point of 6 cycles. We compared the changes of 
PSADT in our patients with those from the historical data in the similar patient population. In the 
published study, 30% of placebo treated patients had positive PSA outcome [8]. In our study, there were 5 
out of 13 patients (38%) (95% CI (0.166 - 1.000) who met the primary endpoint and the PSADT increased 
to > 200% of baseline PSADT. Using one-sided Binomial exact test for proportions, assuming that up to 
30% of patients may have positive PSADT outcome because of placebo effects, there is no significant 
difference between our treatment group and historical data (p = 0.35). (See table 2) 
 
Table 2 PSA kinetics 
 
Percentage of patients with  
post 6 month treatment  
PSADT > 200% of baseline PSADT 
38% (CI 16.6 – 100%) 
P=0.35 
30%* 
PSA velocity (ng/ml/year) 
1.91 (CI 1.17 – 2.65) 
(Before treatment) 
6.07 (CI 2.4 – 12.6) 
(After treatment) 
P=0.078 
*: Historical data from placebo treated patients  
 
PSA velocity 
The statistical analysis is accomplished using mixed effect model, with fixed effects of time and treatment 
and patient-specific random effects of time and treatment. We assumed diagonal covariance structure for 
patient-specific random effect, as well as unstructured covariance for random error. The time unit in this 
analysis is every 365 days. Before treatment, mean PSA velocity is 1.91 ng/ml/year (95% CI (1.165 - 
2.648). After treatment mean PSA velocity increases to 6.07 ng/ml/year (95% CI (2.402 - 12.581), with 
border line significance (p = 0.078) (see Table 2). Six patients showed slowed down PSA increment and 3 
patients even decreased PSA after treatment. Figure 1 shows the maximum PSA percent changes after 6 or 
more cycles of treatment using Waterfall plot. 
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Figure 1 Waterfall plot of PSA declines per subject in this study, with each bar 
representing one patient’s lowest percent decline after 6 – 12 months’ treatment.  
(n = 13). 
Table 3 summarizes the general outcomes of 16 study patients with attempted treatment. As 
demonstrated, three patients (20%) had PSA decrease >25% from baseline with a medium duration of 14 
months (6, 14, and 18 + months). One of them left the town after 6 months treatment and 2 patients were 
on study for 1 year and continued digoxin after the study (duration of 14 months and 18+ months). One 
African American patient had history of Gleason Score 7 (4+3) PCa. He had prostatectomy and salvage 
radiotherapy. His baseline PSADT 8.19 months and day 1 PSA was 2.4 ng/mL. Currently he is still on 
digoxin with most recent PSAs between 1.1 - 1.2ng/ml (50% of baseline value). He is now on 
treatment for 18 months.  
 
Table 3 Tabular Summary of the Outcome of Patients With treatment by digoxin for 6 months (n=16) 
 
% change in PSA from baseline  
Greater than 50% increase  6  
Increase of 0 –50%  5  
Decrease of 0 –50%  3  
Greater than 50% decrease  0  
Removed from study  2*  
Radiographic disease progression  1  
* 1 withdrew because of rising PSA, 1 taken off study for questionable treatment related back pain 
 
Toxicity 
Similar to its tolerability in cardiac patients at levels in the therapeutic range, digoxin was well tolerated 
in patients with prostate cancer. The most frequent non-hematological adverse events were 
gastrointestinal discomfort such as possible reduced appetite. One patient developed acute onset lower 
back pain with unclear etiology during cycle 3 treatment (Table 4). Digoxin was held for possible 
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association but his back pain re-occurred when digoxin was restarted. He was then taken off the study for 
possible toxicity.  
Table 4 Cardiac and other ≥ Grade 2 Adverse Events 
 n (%) 
Bradycardia, asymptomatic  2 (12.5%)  
EKG changes*  3 (18.75%)  
Lower back pain¥  1 (6.25%)  
* 8/16 showed dig effects, 3/16 ST stagging but no concerning arrhythmias  
or other ECG abnormalities to suggest digoxin toxicity.  
¥ possible AE 
 
The target therapeutic range goal (0.8 – 2 ng/ml) digoxin level used in this study is higher than that used 
for cardiology indications such as rate control in atrial fibrillation or systolic heart failure. Patients were 
seen by cardiologist at the oncologist’s discretion either before or during the study if there was an abnormal 
baseline ECGs or prior cardiac history. The median dose of digoxin in this study was 375 mcg daily. 
Digoxin dose was reduced in 2 patients per cardiology recommendation for possible digoxin side effects. 
One patient has baseline right bundle-branch block and sinus bradycardia. At the dose of 500 mcg daily 
with digoxin level of 0.6 ng/ml, he developed left upper arm pain which could be an angina equivalent. His 
dose of digoxin was thus reduced to 375 mcg daily. There were no obvious ECG changes such as ST 
abnormalities. One other patient had dose adjustment from 500 mcg to 375 mcg daily due to sinus 
bradycardia and increased QT interval (QTc still within normal limit). Of the 16 patients, 8 had ECG 
changes that could be consistent with digoxin effect: 5 patients had minor or borderline changes (U waves, 
minor PR prolongation, borderline ST segment abnormalities, and borderline T wave flattening) and 3 
patients had more notable ST segment abnormalities (ST sagging) that were likely digoxin-related. There 
were no concerns for digoxin toxicity throughout the study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Plasma VEGF changes during the treatment course. Only 4 patients had detectable VEGF. One colored 
line represents the changes of VEGF over time in one patient. 
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Correlative studies 
Plasma VEGF was measured at baseline and every 2 cycles. Only 4 patients (25%) had detectable VEGF 
at baseline. The change of VEGF during the digoxin treatment is shown in Figure 2. Both patients who 
were on digoxin for more than 1 year had undetectable VEGF at baseline.  
Discussion 
Based on preclinical and epidemiological data, we designed this pilot phase II study in order to examine 
clinical activity of digoxin for the treatment of recurrent PCa at an early stage. Men with an isolated PSA 
recurrence after initial local treatment represent
 
an ideal population for the evaluation of novel therapies 
based
 
on minimal disease state, indolent natural history, and preference
 
to avoid the adverse effects of 
hormone therapy. The evaluation
 
of novel agents in this setting, however, is hampered by the
 
lack of 
convenient validated end points. Overall or progression-free
 
survival end points are impractical because 
of the long interval
 
between an initial PSA increase and development of metastases or death [19].
 
Although PSADT has not been
 
adequately evaluated as a clinical trial end point, change
 
in PSADT may 
be more sensitive to detect biologic activity than
 
traditional PSA response criteria. It is frequently used in 
the recent clinical trial setting to suggest clinical efficacy [8, 9]. In this study, we measured benefit from 
digoxin by the proportion of patients with positive PSA outcome, defined as PSADT > 200% of baseline. 
Statistical analysis was made to compare our data with historical data to determine the possible efficacy 
of digoxin for the treatment of PCa with rising PSA.  
We found no significant difference of positive PSA outcome between digoxin treated patients and 
placebo treated patients reported in the literature [8]. PSA velocity was not decreased after the treatment 
of digoxin. Although we cannot exactly compare our data with historical data, our results suggests that 
the activity from digoxin treatment cannot be established yet. In a placebo-controlled trial evaluating the 
effect of celecoxib on PSADT in a similar patient population, 20% of 40 men in the placebo group had 
post-treatment PSADT ≥200% of baseline PSADT[8]. A separate study of rosiglitazone versus placebo in 
a similar population showed that 31% of men in the placebo group had a post-treatment PSADT >200% 
of baseline [9]. In our study, 5/13 patients (38%) had PSADT >200% of baseline after 6 months of 
treatment. We need to point out that there are differences in baseline PSADT characteristics in our study 
compared to these prior trials (e.g. PSADTs were between 6 and 24 months[8] or <24 months[9] in the 
other studies, but PSADTs between 3 - 24 months in the current study), and therefore direct comparisons 
of our study with the prior trials is not possible. Therefore, in the absence of a placebo-control, there is 
limitation to interpret the significance of the PSA changes reported here.  
VEGF is expressed by a variety of human solid tumors including PCa [20, 21]. It plays a critical role in 
the pathogenesis and progression of human prostate cancer [22, 23]. VEGF is present in both localized 
and metastatic prostate tumors, and increasing plasma concentration of VEGF correlates with metastatic 
disease progression [24-26]. In patients with metastatic castration-resistant prostate cancer (mCRPC), 
both plasma and urine VEGF levels are independent predictors of overall survival [27, 28]. Since VEGF 
is one of the downstream molecules of HIF-1α, we measured baseline plasma VEGF levels and their 
changes after treatment with digoxin. It is possible that tumor derived VEGF level will be decreased 
when PCa HIF-1α expression is inhibited. From the assay we used, only 4 (25%) patients had detectable 
VEGF in our patients. Two patients had decreased VEGF after treatment while 2 patients had transient 
increase of VEGF during the exposure of digoxin. The patient who responded treatment and has been on 
treatment for more than 18 months did not have detectable VEGF. It is impossible to make any 
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conclusion from this small sample size study about the correlation of VEGF changes with the study drug 
digoxin and clinical outcomes. We need to mention that there are other diverse mechanisms reported to 
be involved
 
in cardiac glycoside-mediated regulation of cell proliferation (reviewed in [29, 30]). One 
mechanism of action was thought to be mainly mediated by alterations in intracellular calcium levels [31, 
32].  
This study has several limitations. First, there was no placebo control in this trial. It has been reported 
that in similar patient populations, placebo-treated patients can have relative stable disease for many 
weeks[8]. In retrospective analyses of the PSA kinetics from patients with biochemically relapsed PCa, 
the calculated PSADT may naturally increase over time in the absence of therapy and may be influenced 
by duration of PSA follow-up. Placebo-controlled randomized clinical trials are thus recommended to 
screen novel agents to mitigate bias because of natural PSADT variability[33]. Second, the patient 
population is too broad with the PSADT from 3 to 24 months. These patients could have very different 
clinical outcomes with this broad range of PSADT [34]. A multi-center trial does have the advantage of 
selecting appropriate patients and finishing study on time.  
For study design, surrogate endpoints for future studies evaluating investigational agents in this patient 
population need to be validated. PSADT and PSA kinetics changes may be acceptable for phase II 
studies, but would have questionable significance in larger phase III studies in the absence of clinical 
endpoints (e.g. metastasis-free survival or overall survival). Metastasis-free survival as a surrogate for the 
survival endpoint is currently being discussed in the clinical research community and may be reasonable 
for studies requiring prolonged follow-up[35]. Interestingly, a preliminary evaluation of several PSA 
measures in the “PSA-only” population seems to suggest that changes in PSA kinetics induced by 
treatments with a variety of experimental agents correlate significantly with metastatic progression[18], 
although these data require prospective confirmation. 
In conclusion, digoxin was well tolerated in PCa patients without obvious cardiac toxicities in this 
pilot phase II, open labeled single center study. We attempted to assess the efficacy of digoxin on 
inhibiting PCa progression as measured by PSADT in men with PSA-recurrent non-metastatic PCa. 
Digoxin showed a prolongation of PSDAT in 38% of the patients, which is not significantly different 
compared to historical cohorts. However, digoxin may have some activity in a small proportion of 
patients but it seems there is no association with plasma VEGF level and it is unclear if its activity is 
related to HIF-1α inhibition. Placebo-controlled, biomarker driven study designs may aid the 
interpretation of future trials evaluating non-hormonal investigational drugs in this patient population. 
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